Contineum Therapeutics

Forecast & Rating8 analysts currently cover Contineum Therapeutics, with about 87.5% giving a positive rating — meaning they expect the stock to rise. The average price target is $22.43, about 70.2% upside from the current price of $13.18. Price targets span a fair range, indicating some disagreement among institutions. For you, this means most professionals who study Contineum Therapeutics closely still see room for the stock to rise. Data as of Oct 7, 2026; for reference only and not investment advice.